Search Results

search

Search Filters

Organization
Prima BioMed
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
March 14, 2017 19:46 ET | Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Mar 14, 2017) -  Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the second cohort comprising six patients has now been...
USA Patent Grants for IMP321 in Cancer
February 28, 2017 19:30 ET | PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Feb 28, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 9,579,382 entitled "Use of Recombinant...
First Half 2017 Operational Update
February 24, 2017 02:13 ET | PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Feb 24, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Highlights Positive recruitment rates for TACTI-mel and AIPAC...
Prima BioMed Receives ~A$860,000 Tax Credit Payment From French Government
February 12, 2017 20:50 ET | Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Feb 12, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), is pleased to announce that its French subsidiary, Immutep S.A.S., has...
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
January 22, 2017 19:00 ET | Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 22, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the submission titled "TACTI-mel, Two ACTive Immunotherapies...
Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
January 19, 2017 18:07 ET | PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Jan 19, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced the first patient has been dosed as part of the enlarged...
Prima BioMed to Maintain NASDAQ Listing
January 18, 2017 02:02 ET | PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Jan 18, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock...
Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
January 11, 2017 18:41 ET | PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Jan 11, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced that the first patient has been dosed for the second cohort...
Prima BioMed Enters New Material Transfer Agreement With CYTLIMIC
January 05, 2017 02:48 ET | Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 5, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, today announced that it has entered into a new collaboration agreement...
Prima Announces New Product Candidate IMP761 -- A LAG-3 Agonist Antibody
January 02, 2017 18:37 ET | Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 2, 2017) -  Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces that it has developed a new early stage product candidate, a...